Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AnHeart Therapeutics Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT06564324
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT06563999
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT06360575
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT06357975
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT06140836
- Locations
- 🇮🇳
Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, India
🇺🇸Local Institution - 0136, Augusta, Georgia, United States
🇺🇸Local Institution - 0221, Des Moines, Iowa, United States
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT06082635
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 420
- Registration Number
- NCT05987332
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 238
- Registration Number
- NCT05204628
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Chang Chun, Ji Lin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.